Fluoxetine and Sertraline Potently Neutralize the Replication of Distinct SARS-CoV-2 Variants.

Autor: Thümmler L; Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany.; Institute for Transfusion Medicine, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany., Beckmann N; Institute of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany., Sehl C; Institute of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany., Soddemann M; Institute of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany., Braß P; Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany., Bormann M; Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany., Brochhagen L; Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany., Elsner C; Institute for Virology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany., Hoertel N; Institute Psychiatry and Neuroscience de Paris, INSERM U1266, Paris Cité University, 75014 Paris, France.; Psychiatry and Addiction Department Corentin-Celton Hospital (AP-HP), 92130 Paris, France., Cougoule C; Institute of Pharmacology and Structural Biology (IPBS), CNRS, University of Toulouse, UPS, 31000 Toulouse, France., Ciesek S; Institute of Medical Virology, University Hospital Frankfurt, 60590 Frankfurt am Main, Germany.; Institute of Pharmaceutical Biology, Goethe-University, 60323 Frankfurt am Main, Germany.; Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Branch Translational Medicine and Pharmacology, 60311 Frankfurt am Main, Germany., Widera M; Institute of Medical Virology, University Hospital Frankfurt, 60590 Frankfurt am Main, Germany., Dittmer U; Institute for Virology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany., Lindemann M; Institute for Transfusion Medicine, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany., Horn PA; Institute for Transfusion Medicine, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany., Witzke O; Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany., Kadow S; Institute of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany., Kamler M; Department of Thoracic and Cardiovascular Surgery, West German Heart Center, University Hospital Essen, 45147 Essen, Germany., Gulbins E; Institute of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany., Becker KA; Institute of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany., Krawczyk A; Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany.; Institute for Virology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany.
Jazyk: angličtina
Zdroj: Viruses [Viruses] 2024 Mar 30; Vol. 16 (4). Date of Electronic Publication: 2024 Mar 30.
DOI: 10.3390/v16040545
Abstrakt: The pandemic caused by SARS-CoV-2 is still a major health problem. Newly emerging variants and long-COVID-19 represent a challenge for the global health system. In particular, individuals in developing countries with insufficient health care need easily accessible, affordable and effective treatments of COVID-19. Previous studies have demonstrated the efficacy of functional inhibitors of acid sphingomyelinase against infections with various viruses, including early variants of SARS-CoV-2. This work investigated whether the acid sphingomyelinase inhibitors fluoxetine and sertraline, usually used as antidepressant molecules in clinical practice, can inhibit the replication of the former and recently emerged SARS-CoV-2 variants in vitro. Fluoxetine and sertraline potently inhibited the infection with pseudotyped virus-like particles and SARS-CoV-2 variants D614G, alpha, delta, omicron BA.1 and omicron BA.5. These results highlight fluoxetine and sertraline as priority candidates for large-scale phase 3 clinical trials at different stages of SARS-CoV-2 infections, either alone or in combination with other medications.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje